MedPath

Shuttle Pharmaceuticals' Ropidoxuridine Shows Promise in Phase 2 Glioblastoma Trial

• Shuttle Pharmaceuticals has successfully dosed the first three patients in a Phase 2 trial of ropidoxuridine for glioblastoma. • The trial is evaluating ropidoxuridine as a radiation sensitizer to enhance the effectiveness of radiation therapy. • Early market response to the announcement was positive, with Shuttle Pharmaceuticals' stock price increasing significantly. • Shuttle Pharmaceuticals is focused on developing therapies that improve cancer treatment outcomes across multiple modalities.

Shuttle Pharmaceuticals Holdings Inc. has announced the successful dosing of the first three patients in its Phase 2 trial evaluating ropidoxuridine as a radiation sensitizer in patients with glioblastoma. This development marks a significant step in the company's efforts to improve cancer treatment outcomes.
The Phase 2 trial is designed to assess the safety and efficacy of ropidoxuridine in combination with radiation therapy for patients with glioblastoma, a particularly aggressive form of brain cancer. Ropidoxuridine is being investigated for its potential to enhance the effects of radiation, thereby improving treatment outcomes.
Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel therapies to improve cancer treatment. The company aims to extend the benefits of cancer treatments by leveraging insights into surgery, radiation therapy, chemotherapy, and immunotherapy.
The market responded positively to the announcement, with Shuttle Pharmaceuticals' stock price experiencing a notable increase. This suggests investor confidence in the potential of ropidoxuridine and Shuttle Pharmaceuticals' approach to cancer therapy.
Further details regarding the trial design, patient population, and specific endpoints were not disclosed in the announcement. Additional data releases are anticipated as the trial progresses.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

MaaT Pharma Share Price Rises on Positive Clinical Trial Results

MaaT Pharma's share price surged over 19% following the announcement of successful Phase 3 clinical trial results for its MaaT013 treatment in acute graft-versus-host disease, marking a significant advancement in gastrointestinal response rates.

Cutia Therapeutics' Novel Drug Shows Promise in Phase II Submental Fat Treatment Trial

Cutia Therapeutics has successfully completed Phase II clinical trials for CU-20401, demonstrating significant efficacy in treating submental fat accumulation. The drug showed a favorable safety profile, marking a potential advancement in aesthetic medicine.

Invion Doses First Patient in Phase I/II Trial of INV043 for Non-Melanoma Skin Cancer

Invion Ltd has dosed the first patient in its Phase I/II clinical trial of INV043 for non-melanoma skin cancer (NMSC).
The trial, conducted in Brisbane, will assess the safety and efficacy of INV043 in treating NMSC, which accounts for over 98% of skin cancers globally.

Orthocell's Remplir Shows Positive Results in Nerve Repair Study, Eyes FDA Clearance

Orthocell's Remplir nerve repair study met all required endpoints, demonstrating safety and effectiveness in repairing peripheral nerves.
The study showed return of motor and sensory function with no adverse tissue reactions, supporting Remplir's biocompatibility.

Shuttle Pharmaceuticals Secures $4.5 Million to Advance Ropidoxuridine Clinical Trials

Shuttle Pharmaceuticals completed a public offering, raising approximately $4.5 million to fund clinical trials and IND-enabling activities.
$2.3 million of the raised capital will be allocated to Theradex Systems, Inc. for Phase II clinical trials of Ropidoxuridine, a radiation sensitizer.

Shuttle Pharma's Ropidoxuridine Phase 2 Trial Expands for Glioblastoma Treatment

Shuttle Pharma expands its Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with the first patient dosed at UVA Cancer Center.
The trial includes 40 patients initially, randomized to two doses, followed by 14 more at the optimal dose, targeting IDH wild-type, methylation-negative glioblastoma.

Shuttle Pharma Doses First Patients in Phase 2 Trial of Ropidoxuridine for Glioblastoma

Shuttle Pharma has initiated a Phase 2 clinical trial of Ropidoxuridine for glioblastoma, a deadly brain tumor with limited treatment options.
The trial will evaluate two different doses of Ropidoxuridine in combination with radiation therapy to determine an optimal dose for patients.

Shuttle Pharma Completes Enrollment for Phase 2 Ropidoxuridine Glioblastoma Trial

Shuttle Pharma finalized agreements with all six planned clinical trial sites for the Phase 2 study of Ropidoxuridine in glioblastoma patients.
The Phase 2 trial will randomize 40 patients with IDH wild-type, methylation negative glioblastomas into two different dose groups.

Shuttle Pharma Completes Enrollment for Phase 2 Glioblastoma Trial of Ropidoxuridine

Shuttle Pharma finalized agreements with all six planned clinical trial sites for its Phase 2 study of Ropidoxuridine in glioblastoma patients.
The Phase 2 trial will evaluate Ropidoxuridine in combination with radiation therapy for patients with aggressive, IDH wild-type, methylation negative glioblastomas.

Shuttle Pharma Expands Glioblastoma Trial with Ropidoxuridine, Boosting Enrollment Sites

Shuttle Pharma broadens its Phase 2 trial for Ropidoxuridine in glioblastoma, increasing the number of active enrollment sites to four.
The trial focuses on IDH wild-type, methylation-negative glioblastoma patients, who currently have limited treatment options and poor prognosis.

Reference News

[1]
Micro Cap Company Is Soaring On Phase 2 Trial Update - The Globe and Mail
theglobeandmail.com · Oct 29, 2024

Shuttle Pharmaceuticals Holdings Inc. (Nasdaq:SHPH) shares surged to $2.25/share (+69.17%) after announcing successful d...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy